AFRINOL
Clinical safety rating
cautionComprehensive clinical and safety monograph for AFRINOL (AFRINOL).
Afrinol is a sympathomimetic amine that acts as a nasal decongestant by stimulating alpha-1 adrenergic receptors in the vascular smooth muscle of nasal blood vessels, causing vasoconstriction and reducing nasal congestion. It also has weak alpha-2 agonist activity.
| Metabolism | Primarily hepatic metabolism via oxidative deamination and glucuronidation; the major enzyme involved is monoamine oxidase (MAO). |
| Excretion | Renal (approximately 70–90% as unchanged drug and metabolites), with about 10% biliary/fecal elimination. Dose adjustment required in renal impairment (CrCl <30 mL/min). |
| Half-life | 9–11 hours in healthy adults; prolonged to 16–18 hours in hepatic cirrhosis and up to 20 hours in severe renal impairment. Clinical context: dosing interval typically 12 hours in normal renal function. |
| Protein binding | 80–90% bound to serum albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 4.0–5.0 L/kg. Indicates extensive tissue distribution, with concentrations exceeding plasma levels in lung, liver, kidney, and brain. |
| Bioavailability | Oral: 40–50% (first-pass metabolism). Intranasal: 70–80% (systemic absorption variable). Intravenous: 100%. |
| Onset of Action | Oral: 30–60 minutes. Intranasal: 5–10 minutes. Intravenous: immediate (within 2–5 minutes). |
| Duration of Action | Oral: 12–24 hours (dose-dependent). Intranasal: up to 12 hours with local decongestant effect. IV: 6–12 hours. Note: Tolerance may develop with prolonged use, reducing duration. |
| Molecular Weight | 343.46 |
Oral: 1 tablet (pseudoephedrine 120 mg, triprolidine 2.5 mg) every 12 hours; maximum 2 tablets per day.
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | CrCl 30-50 mL/min: prolong interval to every 18-24 hours; CrCl <30 mL/min: avoid use. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: use with caution, consider dose reduction; Child-Pugh C: avoid use. |
| Pediatric use | Children 6-12 years: 1/2 tablet (pseudoephedrine 60 mg, triprolidine 1.25 mg) every 12 hours; maximum 1 tablet per day. Children <6 years: not recommended. |
| Geriatric use | Start with 1/2 tablet (pseudoephedrine 60 mg, triprolidine 1.25 mg) every 12 hours; monitor for CNS effects, anticholinergic side effects, and hypertension. |
| 1st trimester | Avoid due to risk of vasoconstriction and potential fetal hypoxia; animal studies show adverse effects. |
| 2nd trimester | Avoid if possible; may reduce uterine blood flow. |
| 3rd trimester | Avoid near term as it may cause uterine contractions and fetal distress. |
Clinical note
Comprehensive clinical and safety monograph for AFRINOL (AFRINOL).
| Placental transfer | Crosses placenta; measurable fetal concentrations. |
| Breastfeeding | Excreted into breast milk in small amounts; potential for irritability and poor feeding in infants. Use with caution, preferably avoid. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Afrinol (pseudoephedrine) is generally considered low risk during pregnancy. First trimester: Some studies suggest a possible association with gastroschisis, but data are inconsistent. Second and third trimesters: Avoid due to risk of uterine vasoconstriction and potential fetal hypoxia, especially near term. Overall, FDA Pregnancy Category C. |
| Fetal Monitoring | Monitor maternal blood pressure and heart rate due to sympathomimetic effects. In pregnancy, assess for signs of uterine irritability or reduced fetal movements. If used near term, monitor fetal heart rate for decelerations. |
| Fertility Effects | Pseudoephedrine may impair fertility in women by reducing uterine blood flow and potentially affecting implantation. It can also cause testicular toxicity in men (reversible). Avoid when trying to conceive. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to pseudoephedrine or sympathomimeticsSevere hypertensionCoronary artery diseaseConcurrent MAOI therapy or within 14 daysNarrow-angle glaucomaUrinary retention due to prostatic hypertrophy
| Precautions | Hypertension, cardiovascular disease, hyperthyroidism, diabetes mellitus, increased intraocular pressure, prostatic hyperplasia; use caution in elderly patients; do not exceed recommended dosage. |
| Food/Dietary | Avoid excessive caffeine intake as it may increase stimulant effects. No significant food interactions known. |
| Clinical Pearls | AFRINOL contains oxymetazoline, an imidazoline sympathomimetic with alpha-adrenergic agonist activity. It causes vasoconstriction in nasal mucosa. Limit use to 3 days to avoid rhinitis medicamentosa. Avoid in patients with narrow-angle glaucoma, severe hypertension, or MAOI use. Onset is within minutes, duration up to 12 hours. |
| Patient Advice | Do not use for more than 3 consecutive days to avoid rebound congestion. · Do not share the bottle with others to prevent infection. · Do not exceed recommended dosage; use only 2-3 sprays per nostril every 10-12 hours as directed. · Avoid using if you have high blood pressure, heart disease, or glaucoma without consulting a doctor. · Consult a doctor if symptoms persist beyond 3 days or if you experience severe side effects like headache, rapid heartbeat, or dizziness. |
Loading safety data…